Considering the surgical safety and presentation of perioperative complications, simultaneous resection of colorectal cancer and liver metastasis after neoadjuvant treatment is not regularly conducted in many centers. Herein, we assessed and compared the surgical safety and incidences of postoperative complications in patients with and without neoadjuvant treatment.
A total of 257 patients who underwent simultaneous resection were included in this single-center, retrospective study. Comparison of the short-term outcomes was performed after propensity score adjustment.
No postoperative death occurred. After matching, the differences from colorectal cancer and liver metastasis were well-balanced. The median operative time, and blood loss and intraoperative transfusion rates did not differ between Group A (without neoadjuvant treatment) and Group B. The morbidity (Group A vs. Group B, 15.4% vs. 19.2%, p = 0.420), and Clavien-Dindo grade of complications (p = 0.632) were also similar. No difference was found when the complications were divided according to the origin (general, colorectal and hepatic). The length of the hospital stays also did not differ between the groups. Ratios of patients with the elevation of some important blood indices related to liver function did not differ, and there was no increase in the number of patients with delayed adjuvant treatment after surgery in Group B.
Simultaneous resection after neoadjuvant treatment was found to be comparably safe. It did not increase morbidity and influence subsequent adjuvant treatment, and may be a treatment option for patients with synchronous liver metastasis.
Clinical trial identification
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Has not received any funding.
The author has declared no conflicts of interest.